Novonesis AI Stock Analysis
Novonesis (NZM) AI Stock Analysis
Novonesis
(Frankfurt:NZM)
No summary available
Novonesis (NZM) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 30.52B
- Dividend Yield
- 0.22%
- Average Volume (3M)
- 14
- Price to Earnings (P/E)
- 39.4
- Beta (1Y)
- 0.35
- Revenue Growth
- 5.55%
- EPS Growth
- 24.50%
- Country
- Germany
- Employees
- 11,641
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Chemicals - Specialty
Novonesis Business Overview & Revenue Model
Company Description
Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends international...
Novonesis Earnings Call Summary
The call was predominantly positive. Novonesis reported solid 7% organic growth, strong margins, broad-based Food & Beverages and Energy momentum, continued innovation, completed strategic investments and confirmed its full-year outlook. The main challenges were the North American dietary supplements downturn, declines in Plant and Tech, elevated CapEx and lower free cash flow, but management expressed confidence in recovery initiatives and the long-term growth trajectory.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Novonesis confirmed full-year 2026 organic sales growth guidance of 7% to 8%, with fourth quarter organic sales growth expected to be in the range of high-single digit and growth mainly volume-driven, supported by a good 1 percentage point contribution from synergies and around 1.5 percentage point from pricing, while exiting certain countries is expected to have a close to 1 percentage point negative effect; adjusted EBITDA margin is expected to be at the higher end of the 37% to 38% range, Food & Health Biosolutions is expected to deliver organic sales growth around the higher end of the group range, Planetary Health Biosolutions around the lower end of the group range, Human Health to slightly decline, Advanced Health & Nutrition to contribute positively led by HMO and supported by Advanced Protein Solutions, and U.S. Dietary Supplements to recover in the second half of 2027; Agricultural, Energy and Tech growth is expected to be broad-based, led by energy and agricultural, CapEx is expected to be towards the higher end of the 12% to 14% of sales, net debt-to-EBITDA ratio is expected to be around 1.8x at year-end, and a noncash revaluation gain on step acquisition of around EUR 35 million is expected in the fourth quarter.
Novonesis Peers Comparison
Overall Rating
SHW65Neutral
PPG62Neutral
ESI60Neutral
EMN57Neutral
SCL55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | $82.10B | 30.94 | 63.49% | 0.94% | 7.03% | 5.95% | |
| 62Neutral | $26.28B | 16.64 | 19.05% | 2.48% | 6.39% | 27.29% | |
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| 60Neutral | $7.77B | 34.93 | 7.39% | 1.08% | 39.62% | -14.83% | |
| 57Neutral | $7.06B | 10.37 | 10.63% | 5.72% | 0.40% | -6.58% | |
| 55Neutral | $1.48B | 334.11 | 0.36% | 2.49% | 10.02% | -90.50% |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:NZM | Novonesis A/S - Adr | 59.50 | 6.57 | 12.40% | |
| EMN | Eastman Chemical Company | 58.77 | 2.84 | 5.07% | |
| PPG | Ppg Industries, Inc. | 117.12 | 22.30 | 23.52% | |
| SHW | Sherwin-Williams | 339.74 | 4.90 | 1.46% | |
| SCL | Stepan Company | 63.48 | 20.83 | 48.86% | |
| ESI | Element Solutions | 29.52 | 4.59 | 18.41% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
